AstraZeneca (AZN) Price & Analysis

Compare

712 Followers

AZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range95.74p - 133.88p

Previous CloseN/A

Volume91.53K

Average Volume (3M)1.96M

Market Cap

£158.45B

Enterprise Value244.29B

Total Cash (Recent Filing)£5.39B

Total Debt (Recent Filing)$31.72B

Price to Earnings (P/E)25.9

Beta1.08

Next Earnings

Jul 29, 2025

EPS Estimate

1.59

Last Dividend Ex-Date

Feb 20, 2025

Dividend Yield260.12%

Share Statistics

EPS (TTM)1.83

Shares Outstanding1,550,670,700

10 Day Avg. Volume2,088,349

30 Day Avg. Volume1,959,268

Financial Highlights & Ratios

PEG Ratio2.70

Price to Book (P/B)5.30

Price to Sales (P/S)0.00

P/FCF Ratio22.50

Enterprise Value/Market Cap1.54

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit5.46

Enterprise Value/Ebitda3.81

Forecast

1Y Price Target

£13,269.69

Price Target Upside12733.36% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Innovation And GrowthAstraZeneca's strong topline performance is driven by significant growth in Oncology and Alliance Revenues.

Market OpportunitiesThe AVANZAR trial is seen as a major catalyst for AstraZeneca, with the potential to unlock a $5-10 billion opportunity in first-line lung cancer.

Product PipelineThe ex-oncology pipeline is expected to contribute significantly to AstraZeneca's sales, with independent expert feedback supporting the potential for upside surprise in top line revenue.

Bears Say

Operational CostsThere is a decline in gross margin and an increase in R&D expenditure, which offsets some leverage over SG&A.

Patent ExpiryThe patent expiry for AstraZeneca’s largest drug in 2026 poses a significant challenge, which the company is attempting to mitigate through the development of fixed dose combinations.

Regulatory ChallengesUncertainties are flagged around the potential MFN implementation and IRA as mechanisms to reduce drug prices.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.03% Insiders

13.26%

Mutual Funds

0.01% Other Institutional Investors

77.22% Public Companies and Individual Investors

Detailed Ownership Overview >

AZN FAQ

What was AstraZeneca PLC’s price range in the past 12 months?

AstraZeneca PLC lowest share price was 95.73p and its highest was 133.88p in the past 12 months.

What is AstraZeneca PLC’s market cap?

AstraZeneca PLC’s market cap is £158.45B.

When is AstraZeneca PLC’s upcoming earnings report date?

AstraZeneca PLC’s upcoming earnings report date is Jul 29, 2025 which is in 20 days.

How were AstraZeneca PLC’s earnings last quarter?

AstraZeneca PLC released its earnings results on Apr 29, 2025. The company reported 1.833p earnings per share for the quarter, beating the consensus estimate of 1.644p by 0.189p.

Is AstraZeneca PLC overvalued?

According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca PLC pay dividends?

AstraZeneca PLC pays a Semiannually dividend of 132.896p which represents an annual dividend yield of 260.12%. See more information on AstraZeneca PLC dividends here

What is AstraZeneca PLC’s EPS estimate?

AstraZeneca PLC’s EPS estimate is 1.59.

How many shares outstanding does AstraZeneca PLC have?

AstraZeneca PLC has 1,550,670,700 shares outstanding.

What happened to AstraZeneca PLC’s price movement after its last earnings report?

AstraZeneca PLC reported an EPS of 1.833p in its last earnings report, beating expectations of 1.644p. Following the earnings report the stock price went up 0.874%.

Which hedge fund is a major shareholder of AstraZeneca PLC?

Currently, no hedge funds are holding shares in GB:AZN

AstraZeneca Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.90%

Trailing 12-Months

Asset Growth

1.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AstraZeneca PLC

AstraZeneca (AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in various therapeutic areas, including oncology, cardiovascular, renal & metabolism, respiratory, and immunology. AstraZeneca is committed to advancing science and technology to deliver life-changing medicines and improve patient outcomes across the globe.

AZN Stock 12 Month Forecast

Average Price Target

13,269.69p

▲(12733.36%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"102":"102p","16501":"16,501p","4201.75":"4,201.8p","8301.5":"8,301.5p","12401.25":"12,401.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13269.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[102,4201.75,8301.5,12401.25,16501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,1365.2492307692307,2626.4784615384615,3887.7076923076925,5148.936923076923,6410.166153846154,7671.395384615385,8932.624615384615,10193.853846153846,11455.083076923078,12716.312307692308,13977.541538461539,15238.77076923077,{"y":16500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,1116.763846153846,2129.507692307692,3142.2515384615385,4154.995384615385,5167.739230769231,6180.4830769230775,7193.226923076923,8205.97076923077,9218.714615384615,10231.458461538461,11244.202307692307,12256.946153846155,{"y":13269.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.02,934.4799999999999,1764.9399999999998,2595.3999999999996,3425.8599999999997,4256.32,5086.78,5917.24,6747.7,7578.16,8408.619999999999,9239.08,10069.539999999999,{"y":10900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":120.53,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >